Clinic of Thoracic Oncology, Instituto Nacional de Enfermedades Respiratorias, Dr. Ismael Cosío Villegas, Ciudad de México, Mexico.
Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, Mexico.
Thorac Cancer. 2021 Apr;12(7):1014-1022. doi: 10.1111/1759-7714.13814. Epub 2021 Mar 4.
Malignant pleural mesothelioma is an infrequent neoplasia with a poor prognosis and the majority of patients already have advanced disease at the time of presentation. Exposure to asbestos is the most important risk factor for malignant pleural mesothelioma. Mesothelioma is a neoplasia with a long preclinical stage that can span from 15 to 40 years.
This was a descriptive, observational, retrospective study of 136 patients with a confirmed diagnosis of mesothelioma, which compared histological subtypes, immunohistochemical biomarkers, concomitant chronic degenerative diseases, tobacco use, age at the time of diagnosis, clinical stage and chemotherapy agents used or other treatments such as radiotherapy and surgery to identify all the factors that impact in the prognosis of overall survival (OS) and progression-free survival (PFS).
A total of 136 patients were included in the study. In the total study population, 84 patients were male (61.8%) and 52 were female (38.2%). Median PFS was nine months (95% confidence interval [CI]: 8.4-9.5 months) and median OS was 12 months (95% CI: 11.3-12.6). The results indicated that the most determining prognostic factors for OS and PFS were cell differentiation measured by immunohistochemical biomarkers, the treatment chosen, and that RECIST was the most significant in the evaluation of patient response to treatment.
Malignant pleural mesothelioma is a cancer with a poor prognosis usually diagnosed at an advanced stage of disease. Our study revealed that the prognostic factors for OS and PS were cell differentiation, the treatment chosen and RECIST.
恶性胸膜间皮瘤是一种罕见的肿瘤，预后不良，大多数患者在就诊时已处于晚期疾病。接触石棉是恶性胸膜间皮瘤的最重要危险因素。间皮瘤是一种具有较长临床前阶段的肿瘤，可跨越 15 至 40 年。
这是一项针对 136 例经证实的间皮瘤患者的描述性、观察性、回顾性研究，比较了组织学亚型、免疫组织化学生物标志物、同时存在的慢性退行性疾病、烟草使用、诊断时的年龄、临床分期以及所使用的化疗药物或其他治疗方法，如放疗和手术，以确定所有影响总生存（OS）和无进展生存（PFS）的预后因素。
共有 136 例患者纳入研究。在总研究人群中，84 例为男性（61.8%），52 例为女性（38.2%）。中位无进展生存期为 9 个月（95%置信区间[CI]：8.4-9.5 个月），中位总生存期为 12 个月（95%CI：11.3-12.6 个月）。结果表明，OS 和 PFS 的最决定性预后因素是免疫组织化学生物标志物测量的细胞分化、所选择的治疗方法，以及 RECIST 在评估患者对治疗的反应方面最为重要。
恶性胸膜间皮瘤是一种预后不良的癌症，通常在疾病晚期诊断。我们的研究表明，OS 和 PS 的预后因素是细胞分化、所选择的治疗方法和 RECIST。
